The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer.
Mercedes Martinez Villacampa
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
Carles Pericay
No relevant relationships to disclose
Ramon Salazar
No relevant relationships to disclose
Carlos López-López
No relevant relationships to disclose
Ferran Losa
No relevant relationships to disclose
M. José Safont
No relevant relationships to disclose
Auxiliadora Gomez
No relevant relationships to disclose
Vicente Alonso
No relevant relationships to disclose
M. Pilar Escudero
No relevant relationships to disclose
Javier Gallego Plazas
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Cristina Gravalos Castro
No relevant relationships to disclose
Sebastiano Biondo
No relevant relationships to disclose
Amalia Palacios
No relevant relationships to disclose
Enrique Aranda
Consultant or Advisory Role - Merck Serono; Roche